48 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 48 of 48 clinical reviews.
Aetna (CVS Health) covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization and step therapy. Learn formulary tier, PA criteria, appeal steps, and how to reduce out-of-pocket costs.
Anthem (Elevance Health) covers Mounjaro for type 2 diabetes with prior authorization and step therapy. Learn formulary tier, PA criteria, appeal steps, and cost-saving options.
Find out whether Cigna covers Mounjaro (tirzepatide) for type 2 diabetes and weight loss, including prior authorization criteria, formulary placement, step therapy rules, and how to appeal a denial.
Find out whether Humana covers Mounjaro (tirzepatide) for type 2 diabetes and weight loss, including formulary placement, prior-authorization criteria, step therapy rules, and how to appeal a denial.
Kaiser Permanente coverage for Mounjaro (tirzepatide) explained: formulary status, prior authorization criteria, step therapy requirements, manufacturer savings card rules, and how to appeal a denial.
State Medicaid coverage for Mounjaro (tirzepatide) varies widely. Learn which states cover it for type 2 diabetes vs. weight loss, prior authorization requirements, step therapy rules, and how to appeal a denial.
TRICARE covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization. Learn formulary tier placement, step therapy requirements, appeal steps for denials, and out-of-pocket cost options for military beneficiaries.
UnitedHealthcare covers Mounjaro (tirzepatide) for type 2 diabetes on Tier 3 with prior authorization. Learn PA criteria, step therapy rules, appeal options, and how to reduce out-of-pocket costs.
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors, unlike single-target drugs, to lower blood sugar, curb appetite, and slow digestion.
Evidence-based guidance on how to safely stop Mounjaro (tirzepatide), including taper schedules, weight regain data from SURMOUNT-4, blood sugar monitoring, and what to expect after discontinuation.
Mounjaro is FDA-approved (May 2022) for type 2 diabetes, plus approved by EMA, MHRA, and Health Canada. See exact approval dates by country.
Evidence-based guide to tirzepatide (Mounjaro) safety during pregnancy and breastfeeding, including FDA labeling, animal data, washout timing, and what remains unknown.
Evidence-based guide to Mounjaro (tirzepatide) dosing for adults aged 30-49. Covers the full titration schedule from 2.5 mg to 15 mg, injection technique, missed-dose rules, and age-specific clinical considerations.
A physician-reviewed, PubMed-cited breakdown of every clinically significant drug-drug interaction for Mounjaro (tirzepatide): mechanism, pharmacokinetics, oral medication absorption, insulin and sulfonylurea risks, and real-world management strategies.
A clinical deep-dive into tirzepatide (Mounjaro) dosing across Child-Pugh classes A, B, and C, covering pharmacokinetics, mechanism, and dose adjustment guidance backed by FDA labeling and primary literature.
Evidence-based guide to tirzepatide (Mounjaro) dosing in patients with renal impairment, including pharmacokinetic data, clinical trial evidence, and practical monitoring recommendations.
A guide to tirzepatide (Mounjaro) food and supplement interactions, covering alcohol, vitamins, herbal supplements, GI-slowing effects, and how to time meals for best results.
A guide to using tirzepatide (Mounjaro) in adults with established cardiovascular disease, covering trial evidence, dosing, safety, and how it compares to other GLP-1 class agents.
A guide to using tirzepatide (Mounjaro) for menopause-related weight gain, covering clinical trial data, dosing protocols, HRT combinations, and realistic outcomes.
A guide to using tirzepatide (Mounjaro) for metabolic syndrome, covering trial evidence, dosing schedules, and real-world outcomes.
A guide to tirzepatide (Mounjaro) for NAFLD and MASLD, covering trial evidence, dosing, liver outcomes, and what patients can realistically expect.
A guide to using tirzepatide (Mounjaro) for obesity with BMI ≥30, covering SURMOUNT trial data, weekly dosing schedules, side-effect management, and insurance realities.
A guide to using tirzepatide (Mounjaro) for PCOS: trial evidence, dosing schedules, hormonal effects, insulin resistance benefits, and how to talk to your provider about off-label use.
Tirzepatide (Mounjaro) is used off-label for prediabetes in high-risk patients. Review the clinical trial data, dosing schedules, side-effect profile, and insurance realities before starting treatment.
Evidence-based guide to Mounjaro (tirzepatide) dosing in adults 65 and older, covering titration schedules, renal adjustments, fall risk, GI tolerability, and deprescribing strategies.
Evidence-based monitoring framework for tirzepatide (Mounjaro) in adults 65 and older, covering renal function, nutritional status, fall risk, and deprescribing considerations.
A detailed look at tirzepatide's origins, mechanism, clinical trial milestones, and FDA approval pathway. Written for patients and clinicians who want the full scientific story behind Mounjaro.
Evidence-based guide to using Mounjaro (tirzepatide) in special populations including transplant recipients, people living with HIV, older adults, and patients with renal or hepatic impairment.
Mounjaro costs about $1,023 monthly without insurance, similar to Ozempic but pricier than Trulicity. See coverage options and how efficacy compares.
A clinical deep-dive into tirzepatide (Mounjaro) manufacturing processes, supply chain disruptions, FDA shortage listings, and Eli Lilly's capacity expansion timeline.
Complete clinical guide to the Mounjaro (tirzepatide) missed-dose protocol, including timing rules, what to skip, pharmacokinetic reasoning, and how tirzepatide's dual GIP/GLP-1 mechanism shapes dosing decisions.
Evidence-based monitoring protocol for tirzepatide (Mounjaro) in adults aged 30 to 49, covering labs, GI tracking, thyroid surveillance, and dose-titration decision points.
A complete guide to the Mounjaro (tirzepatide) monitoring schedule, covering baseline labs, follow-up bloodwork, vital signs, and exam intervals backed by FDA labeling, ADA guidelines, and primary clinical trials.
Evidence-based guide to Mounjaro (tirzepatide) dosing for adults aged 50-64. Covers titration schedule, dose adjustments for kidney function and polypharmacy, and clinical trial data from SURPASS trials.
Evidence-based guide to managing a Mounjaro (tirzepatide) overdose or accidental double dose, including symptoms, timelines, when to seek emergency care, and clinical protocols.
A detailed analysis of Eli Lilly's tirzepatide (Mounjaro) patent portfolio, expected generic entry dates, Paragraph IV challenges, and what patients should expect for biosimilar and generic availability.
Evidence-based guide to how pharmacogenomics and genetic variants influence Mounjaro (tirzepatide) efficacy, side effects, and dosing. Covers GLP-1R and GIPR polymorphisms, GI tolerance genes, and what clinicians should know about personalized prescribing.
A clinical deep-dive into tirzepatide (Mounjaro) pharmacokinetics covering absorption, distribution, metabolism, excretion, half-life, steady-state, and dose-proportionality with PubMed-cited evidence.
Evidence-based safety profile of Mounjaro (tirzepatide) for adults aged 30 to 49, including adverse event rates from SURPASS trials, GI tolerability, and monitoring recommendations.
An evidence-based guide to tirzepatide (Mounjaro) safety for adults aged 50 to 64, covering cardiovascular risk, polypharmacy, hormonal transition, dosing, and individualized monitoring.
A source-bounded guide to Mounjaro in adults 65 and older: trial representation, dosing, kidney function, GI effects, hypoglycemia, frailty, and evidence gaps.
A guide to tirzepatide (Mounjaro) safety for adults ages 18, 29, covering trial data, hormonal effects, fertility, dosing, and monitoring protocols.
A clinician-grade review of tirzepatide (Mounjaro) safety signals, FDA black box warnings, postmarket adverse events, label revisions, and what prescribers should monitor.
Learn the correct Mounjaro (tirzepatide) self-injection technique, including site selection, needle handling, dose titration, and how to minimize injection-site reactions with evidence-based best practices.
Complete clinical guide to tirzepatide (Mounjaro) storage temperatures, shelf life, room-temperature stability windows, and what happens when the cold chain breaks.
A guide to switching between tirzepatide (Mounjaro) and other GLP-1 or dual GIP/GLP-1 medications, including semaglutide, dulaglutide, and liraglutide. Covers mechanism, dose conversion, washout timing, and clinical evidence.
Evidence-based guide to tirzepatide (Mounjaro) dosing in young adults aged 18 to 29, covering escalation schedules, clinical trial data, fertility considerations, and practical tips for this age group.
Evidence-based monitoring guide for young adults aged 18 to 29 on Mounjaro (tirzepatide), covering labs, fertility considerations, mental health screening, and dose-titration safety checks.